Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAX-40279 plus KN046 in advanced or metastatic solid tumors
CTR20220826Phase 2Terminated
- Sponsor
- Guangzhou Zaiji Medical Technology
- Start
- Aug 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of nefextinib, erfonrilimab in Nonhematologic neoplasms, gastric cancer (GC), small cell lung cancer (SCLC), sponsored by Guangzhou Zaiji Medical Technology. Started Aug 2022; status: terminated.
02
Drugs
nefextiniberfonrilimab
03
Conditions
Nonhematologic neoplasmsgastric cancer (GC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20220826.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20220826.